Abstract: A fusion protein for restoring functions of failing immune cells and application thereof. The fusion protein has a functional area for recognizing the failing immune cell and a functional area for conducting activation and amplification on the failing immune cell. The two functional areas are connected through a non-functional amino acid fragment with a certain length. The functional area for recognition uses the immune checkpoint specific antibody to recognize a phenotypic receptor of failing immune cells. The functional area for conducting activation and amplification adopts the cytokine or functionally-similar mutants, a ligand of the phenotypic receptor or functionally-similar mutants or an activating antibody to activate failing immune cells.

Abstract: A multifunctional fusion protein and applications thereof. The multifunctional fusion protein comprising a. functional domains that recognize CD47 positive tumor cells: the extracellular portion of SIRP?, b. functional domains that recognize PD-L1-positive tumor cells: the extracellular portion of PD-1, and c. functional domains that bind to immune cells: high-affinity human IgG1Fc portion. The fusion protein of the invention can meet the needs of the patients for tumor immunotherapy. The recombinant fusion protein can recognize CD47 and PD-L1-positive tumor cells, and bind with immune effector cells containing Fc receptors.

Abstract: A fusion protein for restoring functions of failing immune cells and application thereof. The fusion protein has a functional area for recognizing the failing immune cell and a functional area for conducting activation and amplification on the failing immune cell. The two functional areas are connected through a non-functional amino acid fragment with a certain length. The functional area for recognition uses the immune checkpoint specific antibody to recognize a phenotypic receptor of failing immune cells. The functional area for conducting activation and amplification adopts the cytokine or functionally-similar mutants, a ligand of the phenotypic receptor or functionally-similar mutants or an activating antibody to activate failing immune cells.

Abstract: Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation.

Abstract: Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation.

Abstract: Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation.

Abstract: Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation.